Autoimmune Diseases

The grounding supports immune dysregulation as the central cause, including loss of immune tolerance and autoreactive adaptive or innate immune responses. It also links autoimmune disease research to the gastrointestinal microbiome and intestinal barrier disruption, suggesting that host-microbe interactions may contribute in some settings. No single universal cause is supported for all autoimmune diseases.

The core mechanism is breakdown of immune tolerance, leading to autoimmunity with production of autoantibodies and activation of autoreactive immune cells. The literature grounding also points to dysregulated immune signaling and inflammatory pathways, including JAK/STAT signaling, cytokines, CTLA-4, PD-1, IL-17, and T-cell receptor-related processes. These abnormalities can sustain chronic immune-mediated tissue injury.

The grounding supports immune-system changes across the life course, with autoimmune disease considered alongside neonatal, adult, pregnancy, and old-age immune changes. It also suggests that microbiome disruption and intestinal barrier dysfunction may be associated with disease risk in some contexts. No specific demographic or environmental risk factors are directly supported beyond these broad associations.

The grounding supports treatment at the modality and drug-class level rather than for any one disease. It includes immunomodulation, drug therapy, and therapies targeting immune pathways such as JAK inhibitors, monoclonal antibodies, and agents affecting CTLA-4, PD-1, IL-17, and calcitriol/vitamin D-related pathways. The literature also indicates interest in manipulating the gut microbiota as a therapeutic approach, but no specific standard regimen is supported.